- Improving consistency for cross-border research within the UK
- Partnership with Industry
- Study Pathway
Finding the right investigators and sites for your study
A Central Feasibility Service aims to increase the volume of commercial research placed across Scotland by helping sponsor companies identify appropriate investigators and sites in Scotland to deliver research studies.
Our Feasibility service only covers NHS sites in Scotland. Separate submissions to other UK administrations are required for a UK-wide feasibility.
Two levels of service are available with feedback provided within 14 days.
Requests assessing the top-level feasibility of a study in Scotland:
- does it match with the current standard of care?
- is there a sufficient patient population?
- top-level feedback on study design.
Distributed to the appropriate Topic Network or Specialty Group clinical lead.
- Sponsor actively looking for sites to participate in a study
- Distributed to R&D teams across Scotland and to the Topic Network/Specialty Groups across Scotland.
Health Board R&D offices and Topic Networks/Speciality groups understand current study capability and have established relationships with investigators in each therapy area. Following receipt of a request, local teams will actively support investigators with the accurate and timely completion of questionnaires.
Feasibility or Site ID requests and supporting documentation (protocol, protocol synopsis and questionnaire) should be submitted via email to email@example.com.
Sponsors should submit as much information as possible to allow investigators to fully understand the study and specific delivery requirements. This can include a protocol, protocol synopsis and site feasibility questionnaires.
Once confidentiality arrangements have been confirmed, the request will be circulated to either Health Board R&D departments and/or Topic Network/Speciality group leads where appropriate.
Completed questionnaires or expressions of interest will be returned to the sponsor directly from the Health Board or via our Central Feasibility team as they are made available. A collated summary of responses will be returned to sponsor within 14 days or by the agreed deadline.
Each Health Board in Scotland is a separate legal entity; therefore, confidential disclosure agreements (CDAs) are required for each site. CDAs are signed by the delegated R&D representative at Health Board level. There is no requirement for the proposed investigator to sign.
The Central Feasibility service is operated by the NRS Central Management Team based at the Golden Jubilee National Hospital; a CDA will be required to cover the Feasibility team.
Standard study specific and master CDAs that can be accepted at all sites automatically without changes have been provided.
Use of Sponsor-specific CDAs will likely require negotiation at each Health Board and increase timelines.
If you need a CDA in place before sharing information on your study, please send blinded information to assess which sites are interested. CDAs can then be put in place at interested Boards.